Serum Surfactant Protein-D as Predictor of Disease Severity in Hospitalized COPD Patients

Официальное название

Serum Surfactant Protein-D and Inflammatory Biomarkers as Predictors of Disease Severity in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients

Обзор

evaluation of the serum levels of surfactant protein-D (SP-D), C-reactive protein (CRP), fibrinogen, and peripheral blood neutrophilic and eosinophilic counts in patients with COPD correlation of these biomarkers with clinical, functional, and radiological parameters

Подробное описание

Chronic Obstructive Pulmonary Disease (COPD) is a chronic progressive inflammatory disease of the airways and lungs, mainly caused by cigarette smoking and environmental exposures .It is characterized by airflow limitation that is not fully reversible, with exacerbations and systemic manifestations.

In COPD, there is a significant immune dysregulation, involving both innate and adaptive immune responses.Surfactant Protein D (SP-D) is a lung-specific collectin, produced primarily by alveolar type II cells and Clara cells.SP-D plays a key role in the innate immune defense of the lungs, particularly in modulating inflammation, enhancing phagocytosis, and neutralizing pathogens.

In COPD, the epithelial barrier is compromised, leading to increased leakage of SP-D from the lungs into the bloodstream.As a result, serum levels of SP-D are elevated in COPD patients, and this elevation is positively associated with disease severity and exacerbation frequency.

.SP-D has been proposed as a non-invasive biomarker for COPD severity, progression, and response to therapy.Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability.

Вмешательства

• Диагностический тест Serum Surfactant Protein-D
  Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability

Первичные конечные точки

• evaluation of serum SP-D levels [Срок оценки: baseline]

Вторичные конечные точки (1)

• • Correlation of SP-D with: o Systemic inflammatory markers (CRP, fibrinogen, eosinophils, NLR) o Symptom burden and dyspnea scores (CAT, mMRC) o Prognostic scores (DECAF, APACHE II) o Basic CT chest findings [Срок оценки: baseline]

Критерии участия

Критерии включения

• Adults ≥40 years diagnosed with COPD based on prior diagnosis or spirometry if available.
• Admission for acute exacerbation (AECOPD) in ward or Respiratory ICU.

Критерии исключения

• Active pulmonary infection unrelated to COPD (e.g. tuberculosis, fungal infections)
• Other chronic lung diseases such as asthma, interstitial lung disease, or lung cancer
• Use of systemic corticosteroids for conditions other than COPD exacerbation

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

• Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal-Singer R, Bowler RP. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017 Jun 13;18(1):117. doi: 10.1186/s12931-017-0597-7. PMID 28610627
• He X, Ji J, Zheng D, Luo Z, Luo L, Guo L. Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2025 Feb 14;16:1450798. doi: 10.3389/fimmu.2025.1450798. eCollection 2025. PMID 40028331

Идентификаторы

NCT: NCT07154953 · SP-D in COPD

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗